What was the most concerning outcome from the shareholder meeting?

The most concerning outcome for investors is the advisory vote on the compensation of named executive officers, which was not approved. There were significantly more votes cast against the executive compensation package than in favor, indicating potential shareholder dissatisfaction with the current compensation structure.

Why did some directors not get elected?

For the Class B-1 and Class B-3 Director elections, a quorum was not achieved. Under Delaware law and the company's bylaws, the existing directors in these categories, known as "holdovers," will continue to serve until their successors are duly elected at the 2023 Annual Meeting or until their earlier resignation or removal.

Were there any other significant votes against proposals?

While the election of directors and auditor ratification received strong support, the Amended and Restated CME Group Inc. Omnibus Stock Plan also saw a substantial number of "Against" votes, although it ultimately passed. This, combined with the executive compensation vote, might suggest a more cautious approach from some shareholders regarding equity-based compensation and incentive plans.

What is the significance of the broker non-votes?

Broker non-votes represent shares held by brokers or nominees that have not been voted on a particular proposal because the broker has not received instructions from the beneficial owner. The consistent 21,561,821 broker non-votes across several proposals indicate a significant block of shares that did not have their beneficial owner's vote cast on those matters.

CME 8-K: Shareholder Matters

Summary

CME Group Inc. filed an 8-K on May 5, 2022, detailing the results of its 2022 Annual Meeting of Shareholders held on May 4, 2022. The meeting saw strong shareholder support for the election of most directors and the ratification of Ernst & Young LLP as the independent auditor. However, a significant advisory vote against the compensation of named executive officers and a vote against the Amended and Restated Omnibus Stock Plan indicate potential shareholder concerns regarding executive compensation and equity incentives. A notable outcome was the failure to achieve a quorum for the election of certain Class B directors (B-1 and B-3 categories), resulting in "holdover" directors continuing their service. This situation highlights a governance aspect that may require further attention from management and investors regarding director representation for specific shareholder classes.

Key Highlights

1Shareholders overwhelmingly elected seventeen Equity Directors to serve until 2023, with all nominees receiving substantial "For" votes.
2The appointment of Ernst & Young LLP as the independent public accounting firm for 2022 was ratified with strong shareholder approval.
3The advisory vote on the compensation of named executive officers was NOT approved, with significantly more votes "Against" than "For".
4Shareholder approval was secured for the Amended and Restated Director Stock Plan and the Amended and Restated Employee Stock Purchase Plan.
5The Amended and Restated CME Group Inc. Omnibus Stock Plan received majority approval, but with a notable number of "Against" votes.
6A quorum was not achieved in the election of Class B-1 and Class B-3 Directors, resulting in "holdover" directors continuing in their roles.
7A significant majority of Class A and Class B shares (82.87%) were represented at the Annual Meeting.

CME GROUP INC. 8-K Report, Shareholder Vote Results (May 6, 2022)

Summary

Key Highlights

Frequently Asked Questions